No cerebral vascular anomaly before and after treatment observed - Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking Cardiawave SA
Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults
The trial with VALVOSOFT its disruptive, non-invasive, ultrasound treatment was proven to: be safe and feasible provide a sustained repair of the aortic valve improve quality of life
The First In Human implantation of the ICOMS FLOWMAKER is assured following this financing FineHeart S.A, a preclinical medical device company that has developed theICOMS FLOWMAKER, an Implantable
FineHeart S.A: FineHeart Breaks New Ground With Successful Removal of the ICOMS FLOWMAKER in a 90-day In-vivo Trial
Easy removal with a beating heart without damage to the myocardium 30 days after implantation
Normal heart functioning 60 days after explantation
Completely sealed operation with dedicated implant fixation system
Quick recovery and short hospital stay
Autonomy and free from complications or infection, or structural damage to the heart and vital organs
FineHeart S.A a preclinical medical device company that has developed the
ICOMS FLOWMAKER, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the successful, simple, and breakthrough implantation and removal of its device in a 90-day in-vivo trial.